OVERVIEW

Retooling for Modern Management of Progressive MS: An Interactive, Case-Based Activity is organized by CME Outfitters, LLC.

Live Webcast: Thursday, June 11, 2020, | 6:30 PM - 8:00 PM ET
Credit Expiration Date: Friday, June 11, 2021

Target Audience
Neurologists, MS specialists, PAs, NPs, nurses, and pharmacists

This activity offers CE credit for:
•  Physicians (CME)
•  Nurses (CNE)
•  Pharmacists (ACPE)
•  ABIM (MOC)
•  Other

All other clinicians will gain a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™.

Credit Information
CME Credit (Physicians):
CME Outfitters, LLC, is authorized by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, assigns this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians can earn the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider certified by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can employ for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations authorised by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also earn credit through their state boards.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is authorised by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs).

ABIM/MOC Credit:
On Successful completion of this CME activity, a participant will be able to apply for the evaluation component, enabling the participant to gain up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will receive MOC points commensurate to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Statement of Need
The approval of ocrelizumab for primary progressive multiple sclerosis (PPMS) was groundbreaking, and more recently the MS community bore witness to another major breakthrough in MS management when siponimod was approved for secondary progressive MS (SPMS). Additionally, new investigational agents such as MD1003 (high-dose biotin) and masitinib are also being evaluated for the treatment of PPMS, and clinical data for both show promise for patients with SPMS.

However, despite these advances, studies have shown that gaps in knowledge and performance exist among neurologists and their care teams that poses a barrier to the integration of new and emerging therapies to treat MS in clinical practice.

This CME Outfitters Live and On-Demand webcast will include an interactive, case-based panel discussion highlighting expert faculty who will discuss the symptoms and clinical features of progressive MS, summarize its immunopathology and the mechanisms of action (MOAs) of new and investigational disease-modifying therapies (DMTs), and evaluate the latest clinical evidence on the efficacy and safety of new and emerging therapies for SPMS and PPMS.

Learning Objectives
At the conclusion of this CE activity, participants should be able to:
•  Identify the symptoms and clinic features of progressive MS.
•  Review the immunopathology of progressive MS and the MOAs of new and investigational DMTs.
•  Assess the latest clinic evidence of new and emerging therapies for SPMS and PPMS and engage patients in the shared decision-making process.
•  Unite strategies for SDM to deliver patient-centered care.

The following learning objectives pertain only to those requesting CNE or CPE credit:
•  Understand the symptoms and clinical features of progressive MS.
•  Abstract the immunopathology of progressive MS and the MOAs of new and investigational DMTs.
•  Review the latest clinical evidence on the efficacy and safety of new and emerging therapies for SPMS and PPMS.